{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T05:57:32Z","timestamp":1792130252373,"version":"4.4.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/00920"],"award-info":[{"award-number":["PI18\/00920"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/00789"],"award-info":[{"award-number":["PI21\/00789"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI24\/00702"],"award-info":[{"award-number":["PI24\/00702"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI24\/00702"],"award-info":[{"award-number":["PI24\/00702"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/00920"],"award-info":[{"award-number":["PI18\/00920"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Government of Catalonia | Ag\u00e8ncia de Gesti\u00f3 d'Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["FI_B 00484"],"award-info":[{"award-number":["FI_B 00484"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Government of Catalonia | Ag\u00e8ncia de Gesti\u00f3 d'Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["2023 INV-200035TC2"],"award-info":[{"award-number":["2023 INV-200035TC2"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pleural Mesothelioma (PM) is an aggressive neoplasm of the lung pleura with poor survival rates, highlighting the urgent need for novel therapeutic options. The CDK4\/6 inhibitors abemaciclib and palbociclib have demonstrated promising results in patient-derived xenograft models of PM. In this study, we observed that palbociclib reduced proliferation, leading to increased cell size, enhanced SA-\u03b2-galactosidase activity, and elevated secretion of IL-6 and IL-8 (SASP), all of which are hallmarks of senescence. However, upon drug removal, the cells regrew. To enhance therapeutic efficacy, we attempted to induce cell death in palbociclib-pretreated PM cells with conventional senolytics, such as BH3 mimetics. While some cells showed sensitivity to Bcl-xL inhibitors, neither navitoclax nor the specific Bcl-xL inhibitor A-1331852, nor other BH3 mimetics targeting Bcl-2 (venetoclax) or Mcl-1 (S63845) increased cell death when combined with palbociclib. We explored the activity of signalling pathways after treatment with palbociclib and identified higher Src and STAT3 phosphorylation, as well as activation of the mTORC1 axis. Therefore, we employed inhibitors of these pathways, such as dasatinib, momelotinib or Torin-1, which did not synergise with palbociclib to kill the cells. In contrast, we found that the chemotherapeutic drug cisplatin induces permanent cell cycle arrest and complete senescence in PM cells. While both drugs increased the phosphorylation of \u03b3H2AX, the effects of cisplatin were stronger and more consistent across cell lines. The differential effects of palbociclib and cisplatin on permanent growth arrest were verified by sorting PM cells based on size and \u03b2-galactosidase activity. Our findings underscore the importance of understanding the nature of therapy-induced senescence when assessing the effectiveness of senolytics in different tumour models.<\/jats:p>","DOI":"10.1038\/s41419-026-08696-z","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T16:46:51Z","timestamp":1775839611000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pseudo-senescence induced by palbociclib does not sensitise pleural mesothelioma cells to combinations with senolytics"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3377-7177","authenticated-orcid":false,"given":"Iswarya","family":"Sreeram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7661-4899","authenticated-orcid":false,"given":"S\u00edlvia","family":"Plans-Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8008-5910","authenticated-orcid":false,"given":"Mabel","family":"Cruz-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Aliagas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didac","family":"Palau-Gallinat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9120-664X","authenticated-orcid":false,"given":"Cristina","family":"Mu\u00f1oz-Pinedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9674-5554","authenticated-orcid":false,"given":"Ernest","family":"Nadal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"8696_CR1","doi-asserted-by":"publisher","first-page":"9008","DOI":"10.1073\/pnas.1821510116","volume":"116","author":"R Hassan","year":"2019","unstructured":"Hassan R, Morrow B, Thomas A, Walsh T, Lee MK, Gulsuner S, et al. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc Natl Acad Sci USA. 2019;116:9008\u201313.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8696_CR2","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","volume":"36","author":"V Panou","year":"2018","unstructured":"Panou V, Gadiraju M, Wolin A, Weipert CM, Skarda E, Husain AN, et al. Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma. J Clin Oncol. 2018;36:2863\u201371.","journal-title":"J Clin Oncol"},{"key":"8696_CR3","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636\u201344.","journal-title":"J Clin Oncol"},{"key":"8696_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397:375\u201386.","journal-title":"Lancet"},{"key":"8696_CR5","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00428-008-0689-3","volume":"453","author":"S Dacic","year":"2008","unstructured":"Dacic S, Kothmaier H, Land S, Shuai Y, Halbwedl I, Morbini P, et al. Prognostic significance of p16\/cdkn2a loss in pleural malignant mesotheliomas. Virchows Arch. 2008;453:627\u201335.","journal-title":"Virchows Arch"},{"key":"8696_CR6","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/S1470-2045(22)00062-6","volume":"23","author":"DA Fennell","year":"2022","unstructured":"Fennell DA, King A, Mohammed S, Greystoke A, Anthony S, Poile C, et al. Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial. Lancet Oncol. 2022;23:374\u201381.","journal-title":"Lancet Oncol"},{"key":"8696_CR7","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/s41416-021-01547-y","volume":"125","author":"E Aliagas","year":"2021","unstructured":"Aliagas E, Alay A, Mart\u00ednez-Iniesta M, Hern\u00e1ndez-Madrigal M, Cordero D, Gausachs M, et al. Efficacy of CDK4\/6 inhibitors in preclinical models of malignant pleural mesothelioma. Br J Cancer. 2021;125:1365\u201376.","journal-title":"Br J Cancer"},{"key":"8696_CR8","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/1878-0261.13351","volume":"18","author":"S Paternot","year":"2024","unstructured":"Paternot S, Rasp\u00e9 E, Meiller C, Tarabichi M, Assi\u00e9 J, Libert F. et al. Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4\/6 inhibition. Mol Oncol. 2024;18:866\u201394.","journal-title":"Mol Oncol"},{"key":"8696_CR9","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1002\/1878-0261.12761","volume":"14","author":"T Saleh","year":"2020","unstructured":"Saleh T, Carpenter VJ, Tyutyunyk-Massey L, Murray G, Leverson JD, Souers AJ, et al. Clearance of therapy-induced senescent tumor cells by the senolytic ABT-263 via interference with BCL-XL\u2013BAX interaction. Mol Oncol. 2020;14:2504\u201319.","journal-title":"Mol Oncol"},{"key":"8696_CR10","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1158\/0008-5472.CAN-12-2301","volume":"73","author":"PD Angelini","year":"2013","unstructured":"Angelini PD, Zacarias Fluck MF, Pedersen K, Parra-Palau JL, Guiu M, Morales CB, et al. Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence. Cancer Res. 2013;73:450\u20138.","journal-title":"Cancer Res"},{"key":"8696_CR11","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1016\/j.molcel.2023.10.016","volume":"83","author":"L Crozier","year":"2023","unstructured":"Crozier L, Foy R, Adib R, Kar A, Holt JA, Pareri AU, et al. CDK4\/6 inhibitor-mediated cell overgrowth triggers osmotic and replication stress to promote senescence. Mol Cell. 2023;83:4062\u20134077.e5.","journal-title":"Mol Cell"},{"key":"8696_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40132-0","volume":"14","author":"HM Ashraf","year":"2023","unstructured":"Ashraf HM, Fernandez B, Spencer SL. The intensities of canonical senescence biomarkers integrate the duration of cell-cycle withdrawal. Nat Commun. 2023;14:4527.","journal-title":"Nat Commun"},{"key":"8696_CR13","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1111\/jgs.14969","volume":"65","author":"JL Kirkland","year":"2017","unstructured":"Kirkland JL, Tchkonia T, Zhu Y, Niedernhofer LJ, Robbins PD. The clinical potential of senolytic drugs. J Am Geriatr Soc. 2017;65:2297\u2013301.","journal-title":"J Am Geriatr Soc"},{"key":"8696_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00624-8","volume":"10","author":"R Foy","year":"2024","unstructured":"Foy R, Lew KX, Saurin AT. The search for CDK4\/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays. NPJ Breast Cancer. 2024;10:19.","journal-title":"NPJ Breast Cancer"},{"key":"8696_CR15","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1158\/1078-0432.CCR-16-3083","volume":"23","author":"DR Liston","year":"2017","unstructured":"Liston DR, Davis M. Clinically relevant concentrations of anticancer drugs: a guide for nonclinical studies. Clin Cancer Res. 2017;23:3489\u201398.","journal-title":"Clin Cancer Res"},{"key":"8696_CR16","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.neo.2017.05.003","volume":"19","author":"MA Bonelli","year":"2017","unstructured":"Bonelli MA, Digiacomo G, Fumarola C, Alfieri R, Quaini F, Falco A, et al. Combined inhibition of CDK4\/6 and PI3K\/AKT\/mTOR pathways induces a synergistic anti-tumor effect in malignant pleural mesothelioma cells. Neoplasia. 2017;19:637\u201348.","journal-title":"Neoplasia"},{"key":"8696_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11190","volume":"7","author":"R Yosef","year":"2016","unstructured":"Yosef R, Pilpel N, Tokarsky-Amiel R, Biran A, Ovadya Y, Cohen S, et al. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat Commun. 2016;7:11190.","journal-title":"Nat Commun"},{"key":"8696_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03668-x","volume":"12","author":"D Xu","year":"2021","unstructured":"Xu D, Liang S-Q, Yang Z, Yang H, Bruggmann R, Oberhaensli S, et al. Malignant pleural mesothelioma co-opts BCL-XL and autophagy to escape apoptosis. Cell Death Dis. 2021;12:406.","journal-title":"Cell Death Dis"},{"key":"8696_CR19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41420-020-00348-1","volume":"6","author":"S Arulananda","year":"2020","unstructured":"Arulananda S, O\u2019Brien M, Evangelista M, Harris TJ, Steinohrt NS, Jenkins LJ, et al. BCL-XL is an actionable target for treatment of malignant pleural mesothelioma. Cell Death Discov. 2020;6:114.","journal-title":"Cell Death Discov"},{"key":"8696_CR20","doi-asserted-by":"publisher","first-page":"114.","DOI":"10.1038\/s41420-020-00348-1","volume":"31","author":"S Arulananda","year":"2020","unstructured":"Arulananda S, O'Brien M, Evangelista M, Jenkins LJ, Poh AR, Walkiewicz M. et al. A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma. Cell Death Discov. 2020;31:114.","journal-title":"Cell Death Discov"},{"key":"8696_CR21","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1038\/s41418-020-0564-6","volume":"27","author":"A Shahbandi","year":"2020","unstructured":"Shahbandi A, Rao SG, Anderson AY, Frey WD, Olayiwola JO, Ungerleider NA, et al. BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer. Cell Death Differ. 2020;27:3097\u2013116.","journal-title":"Cell Death Differ"},{"key":"8696_CR22","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1158\/1078-0432.CCR-19-1872","volume":"26","author":"JR Whittle","year":"2020","unstructured":"Whittle JR, Vaillant F, Surgenor E, Policheni AN, Giner G, Capaldo BD, et al. Dual targeting of CDK4\/6 and BCL2 pathways augments tumor response in estrogen receptor\u2013positive breast cancer. Clin Cancer Res. 2020;26:4120\u201334.","journal-title":"Clin Cancer Res"},{"key":"8696_CR23","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/s41418-024-01417-z","volume":"32","author":"C Alcon","year":"2025","unstructured":"Alcon C, Kovatcheva M, Morales-S\u00e1nchez P, L\u00f3pez-Polo V, Torres T, Puig S. et al. HRK downregulation and augmented BCL-xL binding to BAK confer apoptotic protection to therapy-induced senescent melanoma cells. Cell Death Differ. 2025;32:646\u201356.","journal-title":"Cell Death Differ"},{"key":"8696_CR24","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/s41418-024-01439-7","volume":"32","author":"F Jochems","year":"2025","unstructured":"Jochems F, Baltira C, MacDonald JA, Daniels V, Mathur A, de Gooijer MC. Senolysis by ABT-263 is associated with inherent apoptotic dependence of cancer cells derived from the non-senescent state. Cell Death Differ. 2025;32:855\u201365.","journal-title":"Cell Death Differ"},{"key":"8696_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38552-z","volume":"14","author":"DS Potter","year":"2023","unstructured":"Potter DS, Du R, Bohl SR, Chow K-H, Ligon KL, Bueno R, et al. Dynamic BH3 profiling identifies pro-apoptotic drug combinations for the treatment of malignant pleural mesothelioma. Nat Commun. 2023;14:2897.","journal-title":"Nat Commun"},{"key":"8696_CR26","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1093\/carcin\/bgq026","volume":"31","author":"E Varin","year":"2010","unstructured":"Varin E, Denoyelle C, Brotin E, Meryet-Figui\u00e8re M, Giffard F, Abeilard E, et al. Downregulation of Bcl-x L and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy. Carcinogenesis. 2010;31:984\u201393.","journal-title":"Carcinogenesis"},{"key":"8696_CR27","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1177\/1947601910375273","volume":"1","author":"CW Menges","year":"2010","unstructured":"Menges CW, Chen Y, Mossman BT, Chernoff J, Yeung AT, Testa JR. A phosphotyrosine proteomic screen identifies multiple tyrosine kinase signaling pathways aberrantly activated in malignant mesothelioma. Genes Cancer. 2010;1:493\u2013505.","journal-title":"Genes Cancer"},{"key":"8696_CR28","doi-asserted-by":"publisher","first-page":"eabm0756.","DOI":"10.1126\/sciadv.abm0756","volume":"8","author":"C Anerillas","year":"2022","unstructured":"Anerillas C, Herman AB, Rossi M, Munk R, Lehrmann E, Martindale JL. et al. Early SRC activation skews cell fate from apoptosis to senescence. Sci Adv. 2022;8:eabm0756.","journal-title":"Sci Adv"},{"key":"8696_CR29","doi-asserted-by":"publisher","first-page":"460","DOI":"10.2174\/1389450116666150825113500","volume":"17","author":"S Chakradeo","year":"2016","unstructured":"Chakradeo S, W. Elmore L, A. Gewirtz D. Is senescence reversible? Curr Drug Targets. 2016;17:460\u20136.","journal-title":"Curr Drug Targets"},{"key":"8696_CR30","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1158\/0008-5472.CAN-18-3437","volume":"79","author":"T Saleh","year":"2019","unstructured":"Saleh T, Tyutyunyk-Massey L, Gewirtz DA. Tumor cell escape from therapy-induced senescence as a model of disease recurrence after dormancy. Cancer Res. 2019;79:1044\u20136.","journal-title":"Cancer Res"},{"key":"8696_CR31","doi-asserted-by":"publisher","first-page":"17990","DOI":"10.1073\/pnas.1901323116","volume":"116","author":"S AbuHammad","year":"2019","unstructured":"AbuHammad S, Cullinane C, Martin C, Bacolas Z, Ward T, Chen H, et al. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4\/6 inhibitors in melanoma. Proc Natl Acad Sci USA. 2019;116:17990\u201318000.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8696_CR32","doi-asserted-by":"publisher","first-page":"e108599.","DOI":"10.15252\/embj.2021108599","volume":"41","author":"L Crozier","year":"2022","unstructured":"Crozier L, Foy R, Mouery BL, Whitaker RH, Corno A, Spanos C. et al. CDK4\/6 inhibitors induce replication stress to cause long-term cell cycle withdrawal. EMBO J. 2022;41:e108599.","journal-title":"EMBO J"},{"key":"8696_CR33","doi-asserted-by":"publisher","first-page":"e108946.","DOI":"10.15252\/embj.2021108946","volume":"41","author":"B Wang","year":"2022","unstructured":"Wang B, Varela-Eirin M, Brandenburg SM, Hernandez-Segura A, van Vliet T, Jongbloed EM. et al. Pharmacological CDK4\/6 inhibition reveals a p53-dependent senescent state with restricted toxicity. EMBO J. 2022;41:e108946.","journal-title":"EMBO J"},{"key":"8696_CR34","doi-asserted-by":"publisher","first-page":"210125.","DOI":"10.1098\/rsob.210125","volume":"11","author":"BR Pennycook","year":"2021","unstructured":"Pennycook BR, Barr AR. Palbociclib-mediated cell cycle arrest can occur in the absence of the CDK inhibitors p21 and p27. Open Biol. 2021;11:210125.","journal-title":"Open Biol"},{"key":"8696_CR35","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s11033-018-4222-8","volume":"45","author":"P Ozfiliz-Kilbas","year":"2018","unstructured":"Ozfiliz-Kilbas P, Sarikaya B, Obakan-Yerlikaya P, Coker-Gurkan A, Arisan ED, Temizci B, et al. Cyclin-dependent kinase inhibitors, roscovitine and purvalanol, induce apoptosis and autophagy related to unfolded protein response in HeLa cervical cancer cells. Mol Biol Rep. 2018;45:815\u201328.","journal-title":"Mol Biol Rep"},{"key":"8696_CR36","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im S-A, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425\u201339.","journal-title":"Lancet Oncol"},{"key":"8696_CR37","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-17-0754","volume":"23","author":"MN Dickler","year":"2017","unstructured":"Dickler MN, Tolaney SM, Rugo HS, Cort\u00e9s J, Di\u00e9ras V, Patt D, et al. MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+\/HER2\u2212metastatic breast cancer. Clin Cancer Res. 2017;23:5218\u201324.","journal-title":"Clin Cancer Res"},{"key":"8696_CR38","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1093\/annonc\/mdy214","volume":"29","author":"L Malorni","year":"2018","unstructured":"Malorni L, Curigliano G, Minisini AM, Cinieri S, Tondini CA, D\u2019Hollander K, et al. Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. Ann Oncol. 2018;29:1748\u201354.","journal-title":"Ann Oncol"},{"key":"8696_CR39","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/jcb.240630504","volume":"63","author":"HK Oie","year":"1996","unstructured":"Oie HK, Russell EK, Carney DN, Gazdar AF. Cell culture methods for the establishment of the NCI series of lung cancer cell lines. J Cell Biochem. 1996;63:24\u201331.","journal-title":"J Cell Biochem"},{"key":"8696_CR40","doi-asserted-by":"publisher","first-page":"6842","DOI":"10.1158\/1078-0432.CCR-13-0736","volume":"19","author":"E Nadal","year":"2013","unstructured":"Nadal E, Chen G, Gallegos M, Lin L, Ferrer-Torres D, Truini A, et al. Epigenetic inactivation of microRNA-34b\/c predicts poor disease-free survival in early-stage lung adenocarcinoma. Clin Cancer Res. 2013;19:6842\u201352.","journal-title":"Clin Cancer Res"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08696-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08696-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08696-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T08:00:42Z","timestamp":1776067242000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08696-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8696"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08696-z","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"24 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EN received research funding from Roche, Pfizer, Merck-Serono and Bristol Myers Squibb (BMS), participated in advisory boards or received honoraria from Amgen, Apollomics, AstraZeneca, BeiGene, BMS, Boehringer-Ingelheim, Daiichi-Sankyo, Genmab, Illumina, Johnson & Johnson, Lilly, Merck Sharp & Dohme (MSD), Merck-Serono, Pfizer, Pierre Fabre, Qiagen, Regeneron, Roche, Sanofi and Takeda, and received travel support from Roche, Takeda, Janssen, and MSD.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"388"}}